An inexpensive anti-cancer drug

Mebendazole, a common FDA-approved antiparasitic medication, is being studied for drug repurposing in oncology. Preclinical and clinical studies suggest it acts as an anticancer agent by disrupting cancer cell division (tubulin inhibition), stopping new blood vessel formation (angiogenesis), and triggering programmed cell death (apoptosis) in various malignancies.